<DOC>
	<DOC>NCT00156884</DOC>
	<brief_summary>This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.</brief_summary>
	<brief_title>A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostate cancer.</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>adenocarcinoma of the prostate life expectancy &gt; 3 months, symptomatic from bone metastases radiologic evidence of metastatic bone disease stable level of pain control &gt;18 years ability to complete assessments prior treatment (chemo) &gt; 4 weeks previous discontinued antiandrogens for &gt; 4 weeks prior strontium therapy previous hemibody RT within 6 weeks previous cytotoxic chemotherapy within 4 weeks use of bisphosphonate medications within 4 weeks change in steroid dose within 4 weeks active uncontrolled infection impending or present spinal cord compression significant neurological disorder impending pathological fracture severe urinary incontinence</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>cisplatin</keyword>
	<keyword>strontium-89</keyword>
	<keyword>phase II</keyword>
</DOC>